Problem-solving articles |
|
Pokrovsky V.I., Fokina E.G.
Diphtheria: Forgotten, but not gone
|
4-12 |
Epidemic situation |
|
Yermolovich M.A., Dronina A.M., Samoilovich E.O.
The epidemic process of acute parvovirus infection in the Republic of Belarus
|
13-20 |
|
Kuznetsova R.S.
The incidence of hepatitis C in the Samara Region
|
21-26 |
Original investigations |
|
Akimkin V.G., Alimov A.V., Polyakov V.S.
Epidemiological efficiency of the use of bacteriophages for prevention of acute bacterial respiratory infections in organized groups
|
27-34 |
|
Feldblyum I.V., Alyeva M.Kh., Markovich N.I., Isaeva N.V.
Colorectal cancer in the Perm Territory: Epidemiological aspects
|
35-39 |
|
Chefranova Zh.Yu., Kazakova E.E., Bashkirev A.A., Khomyakov S.V., Shmykova Е.А., Marushchenko E.A.
Microbiological monitoring and epidemiological surveillance of nosocomial infections at a multiprofile hospital of the Belgorod Region
|
40-44 |
|
Tselipanova E.E., Galkina L.A., Savitskaya N.A.
Results of clinical and laboratory tests for opportunistic infections during the first year of life in infants with recurrent acute respiratory diseases
|
45-49 |
|
Vilnits A.A., Skripchenko N.V., Ivanova M.V., Ivashchenko I.A., Mazaeva E.M.
Current features of Haemophilus meningitis in children
|
50-54 |
|
Makashova V.V., Kuznetsov S.D., Tutelyan A.V., Shabalina S.V.
Clinical and genetic relationships in patients with chronic hepatitis C
|
55-59 |
|
Bilalova A.R., Makashova V.V., Aleshina O.S., Astrina N.I., Shabalina S.V., Omarova Kh.G.
Features of the hemostatic system in liver cirrhosis of various origins
|
60-64 |
Reviews and lectures |
|
Titova S.V., Monakhova E.V.
Potential danger of nontoxigenic Vibrio cholerae strains containing genes for toxin-coregulated pili adhesion
|
65-72 |
Exchange of experience |
|
Kravchenko A.V., Orlova-Morozova E.A., Shimonova T.E., Kozyrev O.A., Nagimova F.I., Zakharova N.G., Ivanova E.S., Sonin D.B., Chernova O.E., Tonkikh O.S., Yakovlev A.A., Kurina N.V., Pokrovsky V.V., Bychko V.V., Vostokova N.V., Zozulya O.V.
The efficacy and safety of Elpivirine as part of a 24-48-week antiretroviral therapy regimen versus an Efavirenz-containing regimen
|
73-80 |
Русский
